Biocept Inc (BIOC) 4.88 $BIOC
Nasdaq stocks posting largest percentage decreases
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Virobay Announces The Appointment Of James Welch As Chief Financial Officer
PR Newswire - Wed Jun 25, 11:00AM CDT
Virobay, Inc., a clinical stage pharmaceutical company with a broad platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseases and fibrosis, today announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014.
5 Stocks Setting Up to Break Out
at The Street - Mon Jun 23, 8:37AM CDT
These stocks look poised to break out and trade higher from current level.s
5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels.
Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 2013-2017
M2 - Fri Jun 06, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wsb26b/the_market_for) has announced the addition of the "The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)" report to their offering. The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Circulating tumor cells (CTCs) are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs and forming new tumors. These cells that leave the primary tumor are able to colonize distant organs in the body and initiate the process of metastasis; however, their biology is still not entirely elucidated. Circulating tumor cells have tremendous utility in cancer research, aiding scientists in deciphering the complex biology of cancer metastasis. Besides the applications in cancer research, the detection and analysis of circulating tumor cells has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. This report, The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells, is Kalorama's detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies. Analyst Adriana Rusu informs readers of the scientific basis of CTCs in an understandable fashion, and constructs models of revenue opportunity based on several dimensions - application area, cancer type and region - that can assist with business planning efforts. Despite their potential, the detection and analysis of circulating tumor cells has been a challenging endeavor, and their significance in cancer not completely understood. Progress in the field of CTC-based cancer diagnostics and therapeutics has been thus far hampered by the rarity of these cells and the difficulty to isolate them from the patient's blood. Nonetheless, in the past decade, numerous technological advances have contributed to a renewed interest in this field. The report considers these challenges and trends in the markets and provides data on the following: - Introduction and Overview of Biolgy Behind CTCs - Market and Forecast to 2017 For CTCs-based Technologies - Market Breakdown by Type of Cancer - Market Breakdown by Application Type (Research, Diagnostics) - Market Breakdown by Geographic Region - Current Isolation and Identification Methods - Uses in Prognosis, Diagnosis, Drug Development and Other Research - CTCs-based Products and Competitors - The Current State of Cancer Treatment, Incidence and Other Helpful Statistics - Collaboration and Partnerships The following companies are profiled: - AdnaGen AG - Advanced Cell Diagnostics, Inc. - ApoCell, Inc. - Aviva Biosciences Corporation - Biocept, Inc. - Biofluidica - BioView Ltd. - Celula, Inc. - Clearbridge Biomedics - Creatv MicroTech, Inc. - Cynvenio Biosystems - CytoTrack ApS - Epic Sciences - Fluidigm Corporation - Fluxion Biosciences, Inc. - Ikonisys, Inc. - Miltenyi Biotec GmbH - On-Q-ity - Parsortix/ANGLE - RareCells Diagnostics - ScreenCell - Silicon Biosystems - TeloVISION LLC - Veridex, LLC - Vitatex Inc. For more information visit http://www.researchandmarkets.com/research/ws...market_for
Nasdaq stocks posting largest volume increases
AP - Tue Jun 03, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Biocept Expands Breast Cancer Offering
GlobeNewswire - Mon Jun 02, 8:35AM CDT
Blood-based OncoCEE-BR(TM) Platform now Includes Estrogen Receptor Testing
Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program
GlobeNewswire - Mon Mar 24, 10:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) and biomarker analysis, today announced that it has appointed Raaj Trivedi as Vice President - Commercial Operations.
Biocept, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
10-Q: MALVERN BANCORP, INC.
Edgar Online - Wed Feb 12, 3:35PM CST
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations
Nasdaq stocks posting largest percentage decreases
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Virobay Announces The Appointment Of James Welch As Chief Financial Officer
PR Newswire - Wed Jun 25, 11:00AM CDT
Virobay, Inc., a clinical stage pharmaceutical company with a broad platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseases and fibrosis, today announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014.
5 Stocks Setting Up to Break Out
at The Street - Mon Jun 23, 8:37AM CDT
These stocks look poised to break out and trade higher from current level.s
5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels.
Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) 2013-2017
M2 - Fri Jun 06, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wsb26b/the_market_for) has announced the addition of the "The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)" report to their offering. The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Circulating tumor cells (CTCs) are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs and forming new tumors. These cells that leave the primary tumor are able to colonize distant organs in the body and initiate the process of metastasis; however, their biology is still not entirely elucidated. Circulating tumor cells have tremendous utility in cancer research, aiding scientists in deciphering the complex biology of cancer metastasis. Besides the applications in cancer research, the detection and analysis of circulating tumor cells has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. This report, The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells, is Kalorama's detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies. Analyst Adriana Rusu informs readers of the scientific basis of CTCs in an understandable fashion, and constructs models of revenue opportunity based on several dimensions - application area, cancer type and region - that can assist with business planning efforts. Despite their potential, the detection and analysis of circulating tumor cells has been a challenging endeavor, and their significance in cancer not completely understood. Progress in the field of CTC-based cancer diagnostics and therapeutics has been thus far hampered by the rarity of these cells and the difficulty to isolate them from the patient's blood. Nonetheless, in the past decade, numerous technological advances have contributed to a renewed interest in this field. The report considers these challenges and trends in the markets and provides data on the following: - Introduction and Overview of Biolgy Behind CTCs - Market and Forecast to 2017 For CTCs-based Technologies - Market Breakdown by Type of Cancer - Market Breakdown by Application Type (Research, Diagnostics) - Market Breakdown by Geographic Region - Current Isolation and Identification Methods - Uses in Prognosis, Diagnosis, Drug Development and Other Research - CTCs-based Products and Competitors - The Current State of Cancer Treatment, Incidence and Other Helpful Statistics - Collaboration and Partnerships The following companies are profiled: - AdnaGen AG - Advanced Cell Diagnostics, Inc. - ApoCell, Inc. - Aviva Biosciences Corporation - Biocept, Inc. - Biofluidica - BioView Ltd. - Celula, Inc. - Clearbridge Biomedics - Creatv MicroTech, Inc. - Cynvenio Biosystems - CytoTrack ApS - Epic Sciences - Fluidigm Corporation - Fluxion Biosciences, Inc. - Ikonisys, Inc. - Miltenyi Biotec GmbH - On-Q-ity - Parsortix/ANGLE - RareCells Diagnostics - ScreenCell - Silicon Biosystems - TeloVISION LLC - Veridex, LLC - Vitatex Inc. For more information visit http://www.researchandmarkets.com/research/ws...market_for
Nasdaq stocks posting largest volume increases
AP - Tue Jun 03, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Biocept Expands Breast Cancer Offering
GlobeNewswire - Mon Jun 02, 8:35AM CDT
Blood-based OncoCEE-BR(TM) Platform now Includes Estrogen Receptor Testing
Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program
GlobeNewswire - Mon Mar 24, 10:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) and biomarker analysis, today announced that it has appointed Raaj Trivedi as Vice President - Commercial Operations.
Biocept, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
10-Q: MALVERN BANCORP, INC.
Edgar Online - Wed Feb 12, 3:35PM CST
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations
